Navigation Links
IUPUI chemists develop Distributed Drug Discovery: Finding drugs for neglected diseases
Date:6/15/2009

INDIANAPOLIS Researchers from Indiana University-Purdue University Indianapolis (IUPUI) have developed Distributed Drug Discovery (D3), a new low-cost strategy to accelerate the discovery of drugs to treat neglected diseases such as tuberculosis, leprosy, leshmaniasis, dengue fever, and Chagas disease.

Even in times of economic prosperity, the pharmaceutical industry has often been reluctant to get involved in developing treatments for diseases that occur primarily in low income countries. The low cost D3 approach, involving distributed global educational resources at the early stage of discovery, is even more attractive in this time of global economic downturn.

A distributed problem solving process breaks large problems into small pieces which are "distributed" to multiple, small, low-cost sites to obtain a solution. For decades astronomers have enlisted the help of the public, asking individuals around the world to leave their home computers on overnight. While normally idle, each one of these computers looks for patterns in a small subset of the incredibly large amount of space noise signals received by arrays of radio telescopes scanning the skies.

Two studies, published this year in the Journal of Combinatorial Chemistry, detail the first two steps in D3, developed by William Scott, Ph.D., research professor, and Martin J. O'Donnell, Ph.D., IUPUI Chancellor's Professor, both of the Department of Chemistry and Chemical Biology at IUPUI.

D3 uses a distributed problem approach at all three key stages of drug discovery. Step one is identifying candidate drug molecules. To do this, IUPUI researchers are soliciting the global advice of computational experts in neglected disease areas and utilizing the computational power of multiple personal computers around the world to scan the almost infinite number of molecules which the D3 synthesis process could make to identify the smaller number of drug candidate molecules they should make. Dr. Scott and Dr. O'Donnell believe this will lead to the selection, synthesis and development of innovative and inexpensive drugs to treat these neglected diseases.

In the second step, D3 uses an innovative, distributed educational approach to synthesize the candidate molecules. Undergraduate and graduate chemistry students from around the world synthesize subsets of these candidate molecules as part of their normal training in synthetic chemistry. Currently students at IUPUI, the University of Indianapolis, and universities in Poland, Russia and Spain have demonstrated their ability to make the molecules (or portions of the molecules) that can be identified by the personal computers as potential candidates for drug discovery.

Initial results are very promising, according to Dr. Scott. "While learning chemistry synthesis skills students across the globe synthesize new molecules to be tested as drug leads. The molecules meet the same quality standards as those required in industry. At the same time the students enthusiastically participate in the synthesis laboratories. They enjoy seeing how their work will advance science that is going to make a difference to individuals suffering from diseases which have been ignored," he said.

The third step in D3 is biological testing of the molecules synthesized by the students. Dr. Scott and Dr. O'Donnell hope the success of distributed problem solving at the computational and synthetic stages of drug discovery will encourage their biological colleagues to develop simple, inexpensive tests to enable students worldwide to participate in this final stage of drug-lead discovery. Currently some of the molecules made are being evaluated through the resources of the National Institutes of Health. In the future, promising drugs will then go on to pre-clinical trials.

"The coordinated and recombined results of these distributed D3 resources can economically accelerate the identification of leads in the early stages of the drug discovery process. Simultaneously, this effort provides educational and job opportunities in both the developed and developing worlds, while building cultural and economic bridges for the common good," Dr. Scott and Dr. O'Donnell wrote in an accompanying perspective article.


'/>"/>

Contact: Cindy Fox Aisen
caisen@iupui.edu
317-274-7722
Indiana University
Source:Eurekalert

Related medicine news :

1. IUPUI scientists report first 3-D view of anti-cancer agent
2. Computers help chemists fight emerging infections
3. UIC chemists characterize Alzheimers neurotoxin structure
4. Iowa State chemists track how drug changes, blocks flu virus
5. Stevens chemists identify compounds to lure nutria, a rat-like pest ravaging Gulf Coast wetlands
6. Roche Symposium Showcases Accomplishments of Next Generation of Chemists
7. Brown chemists create cancer-detecting nanoparticles
8. UCR chemists use green chemistry to produce amines, chemical compounds used widely in industry
9. Informex Invites Young Chemists to Attend InformexUSA
10. New Reaxys Solution Improves Workflow Quality and Efficiency for Chemists
11. Waters Corporation Announces U.S. Drug Enforcement Administration Acquires Waters ACQUITY UPLC System to Train Forensic Chemists in Drug Screening and Profiling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... February 21, 2017 , ... Doctors on Liens has ... by Dr. Kendell Mendonca , to its growing network of doctors in Central ... injuries stemming from car accidents such as whiplash, back pain, neck pain, hip and ...
(Date:2/21/2017)... Carrollton, Ga. (PRWEB) , ... February 21, 2017 , ... ... industry. To simplify the secure exchange of data across industry solutions, Fogo Data ... in the power of community. A healthy community is one in which all ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... the predictive analytic firm Predixion’s Healthcare IT practice. Predixion, which raised $42M+ to ... backed by giants including Accenture, GE Ventures, and Software AG , will ...
(Date:2/21/2017)... ... February 21, 2017 , ... CLICKco LLC, a company dedicated ... are now available for purchase on RonnieColemanNutrition.com, a popular website for health and ... health-conscious consumers who love coffee but are looking to add more protein to ...
(Date:2/20/2017)... ... , ... Nancy Johnston Toll marks her debut in the publishing ... Bump in the Road ” (published by Xlibris). Inspired from her personal experiences, this ... ups and downs experienced by anyone going through cancer treatment and how one can ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)...  Luminex Corporation (NASDAQ: LMNX ) (the "Company") ... initiation of a quarterly cash dividend to its shareholders, the ... be payable on April 14, 2017 to shareholders of record ... The board of directors intends for the ... to holders of its common stock, representing a planned annual ...
(Date:2/21/2017)... , Feb. 21, 2017  /PR Newswire/ -- ... pleased to announce the launch of Modern Retina ... website for retina specialists. Built upon the ... focuses on the latest innovations in the areas ... and practice management. By meeting current informational needs and ...
(Date:2/21/2017)... 2017   BeyondSpring Pharmaceuticals , a clinical ... innovative immuno-oncology cancer therapies, today announced that the ... Phase 2 trial of BeyondSpring,s innovative lead asset, ... cell lung cancer (NSCLC) with Docetaxel has been ... Clinical Immuno-Oncology Symposium in Orlando, Fla. ...
Breaking Medicine Technology: